« Return to News | CROs/Service Providers

PPD 3Q Earnings Up, Cuts 2008 Guidance

Wednesday, October 22, 2008 09:04 AM

PPD, a contract research organization (CRO), reported third quarter revenue increased 11.6% to $398.5 compared with $357.2 million for the third quarter of 2007. Diluted earnings per share jumped 34% to $0.43 per share.

The company lowered its full-year revenue projection to between $1.47 billion and $1.49 billion from $1.54 billion to $1.59 billion as a result of a FDA delay in approving diabetes drug alogliptin.

Income from operations for the third quarter rose 35% to $71.3 million. 

New business authorizations for the third quarter amounted to $705  million, a 23.6 percent year-over-year increase. Contract cancellations for the quarter were $207.7 million, for a book-to-bill ratio of 1.36. The company's cancellation rate was 24%. Backlog at Sept. 30 was $3 billion, a year-over-year increase of 20%.

"We were very pleased with the level of new business wins and the rebound from the second quarter," said Fred Eshelman, CEO of PPD. "While third quarter revenue growth was moderately slower than expected, demand for drug development services remains strong, and we believe our new authorizations and existing backlog should help drive future top line sustained growth."

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

December 17

Medici Global says its Alzheimer's Facebook page demonstrates the need for more early detection trials

Analysts: Expect more equity purchases of CROs in 2013

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

January 2013

Parexel celebrates 30 years of change, growth
CRO's founder and chairman reflects on challenges of the past, present and future

Strategies for increasing patient diversity in trials
Sponsors look to improve racial, ethnic recruitment without going overseas

Already a subscriber?
Log in to your digital subscription.

Purchase the January issue.

Subscribe to The CenterWatch Monthly.

December 2012

Publicity, regulation tightening reins on use of KOLs
Debate rages over need to revamp how sponsors use, pay medical experts

Time may be right to makeover the investigator brochure
Size, complexity prevent critical document from being thoroughly read

Already a subscriber?
Log in to your digital subscription.

Purchase the December issue.

Subscribe to The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.